Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pyxis Oncology (PYXS) Shares Outstanding (Diluted Average): 2024-2025

Historic Shares Outstanding (Diluted Average) for Pyxis Oncology (PYXS) over the last 2 years, with Sep 2025 value amounting to $62.6 million.

  • Pyxis Oncology's Shares Outstanding (Diluted Average) rose 3.03% to $62.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.6 million, marking a year-over-year increase of 3.03%. This contributed to the annual value of $58.4 million for FY2024, which is N/A change from last year.
  • Per Pyxis Oncology's latest filing, its Shares Outstanding (Diluted Average) stood at $62.6 million for Q3 2025, which was up 1.03% from $61.9 million recorded in Q2 2025.
  • Over the past 5 years, Pyxis Oncology's Shares Outstanding (Diluted Average) peaked at $62.6 million during Q3 2025, and registered a low of $51.3 million during Q1 2024.
  • Moreover, its 2-year median value for Shares Outstanding (Diluted Average) was $60.7 million (2024), whereas its average is $59.5 million.
  • Data for Pyxis Oncology's Shares Outstanding (Diluted Average) shows a peak YoY grew of 19.03% (in 2025) over the last 5 years.
  • Over the past 2 years, Pyxis Oncology's Shares Outstanding (Diluted Average) (Quarterly) stood at $58.4 million in 2024, then grew by 3.03% to $62.6 million in 2025.
  • Its last three reported values are $62.6 million in Q3 2025, $61.9 million for Q2 2025, and $61.0 million during Q1 2025.